Detlef Wencker, MD
Advanced Heart Failure and Transplant Cardiology · Tyler, TXNPI 1285634881
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,866 of the $7,655 with a category attached, or 63.6%. 18 manufacturers reported payments, led by Abbott at 29.8% of the total. Reporting peaked in 2019 at $2,174 and has fallen 51.7% since, to $1,050 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in TX, where the typical reported total is $11,093.
Across 104 payments — averaging $73.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$2K
- Cvrx, Inc.$1K
- Novartis$573
- Nuwellis, Inc.$492
- Abiomed$309
- plus $888 from 12 others
What the payments were for
- Travel & lodging$2,78936%
- Food & beverage$4,86664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 28 | $2,278 |
| Medtronic(2 entities) | 9 | $1,649 |
| Cvrx, Inc. | 7 | $1,466 |
| Novartis | 20 | $573 |
| Nuwellis, Inc. | 6 | $492 |
| Abiomed | 3 | $309 |
| E.r. Squibb & Sons, L.L.C. | 5 | $205 |
| Daxor Corporation | 2 | $140 |
| Merck | 5 | $100 |
| Alnylam Pharmaceuticals Inc. | 4 | $98 |
| Boehringer Ingelheim | 3 | $80 |
| AstraZeneca | 4 | $72 |
| Impulse Dynamics (USA) Inc. | 1 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $43 |
| Pfizer | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 1 | $29 |
| Haemonetics Corporation | 1 | $24 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartWare HVAD$1,320
- Barostim Neo System$1,171
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$742
- HeartMate 3 Left Ventricular Dev$526
- HeartMate 3 Left Ventricular Assist Device$279
- AQUADEX SMARTFLOW CONSOLE$270
- HeartMate$270
- Impella$253
- LEQVIO$210
- CARDIOMEMS$149
- CAMZYOS$122
- Aquadex$121
- BVA-100$120
- AZURE XT DR MRI SURESCAN$113
How this compares
$7,655 in reported general payments places this provider in the 45th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 160 | $182,707 |
| JardianceEmpagliflozin | 100 | $132,451 |
| EliquisApixaban | 29 | $32,656 |
| FarxigaDapagliflozin Propanediol | 23 | $19,439 |
| Metoprolol Succinate | 160 | $2,796 |
| Spironolactone | 210 | $2,567 |
| Torsemide | 74 | $1,570 |
| Potassium Chloride | 38 | $1,172 |
| Rosuvastatin Calcium | 49 | $1,117 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $1,100 |
| Bumetanide | 40 | $1,044 |
| Atorvastatin Calcium | 44 | $817 |
| Chlorthalidone | 44 | $708 |
| Furosemide | 90 | $628 |
| Amiodarone Hcl | 27 | $602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $573 | $182,707160 claims |
| Boehringer IngelheimJardiance | $80 | $132,451100 claims |
| PfizerEliquis | $35 | $32,65629 claims |
| AstraZenecaFarxiga | $72 | $19,43923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Tyler
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Aasim AfzalPlano$336K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
- Arvind BhimarajHouston$216K
- Jerome ThomasAustin$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.